Biophan - Die Termine - 500 Beiträge pro Seite

[CyberCoach]

Hier für die Neueinsteiger die neuesten Termine .

Bitte keine News, Ad-Hocs, sonstiges posten, einfach nur Time-Schedule, für den Rest haben wir schon Threads.

List of Conferences


Date
(Company Representative)


Conference/Seminar
October 17-21
John Lanzafame / Sarah Cooper
Attend/Exhibit
Licensing Executives Society USA-Canada Annual Mtg.
Marriott Copley Place
Boston, MA
www.usa-canada.les.org/2004annual/

October 18-20
Michael Weiner
Stu MacDonald
Jeff Helfer
Attend
Cleveland Clinic 2004 Medical Innovation Summit
Intercontinental Conference Center, Cleveland, OH
www.clevelandclinic.org/innovations/home.htm
October 21-22
John Lanzafame

Present/Attend
Medtech Insight Conference " Investment In Innovation" . A Preview of Early Stage Medical Companies
The Westin Copley Place Hotel, Boston, MA
www.medtechinsight.com

October 22
Michael Weiner

Present
WallSt.net Small Capital Conference Four Seasons Hotel, Beverly Hills, CA
www.wallst.net/smallcap.asp

October 25-26
Michael Riedlinger
John Lanzafame
Exhibit
NanoMedicine Summit 2004
Intercontinental Hotel and MBNA Conference Center
Cleveland, OH
www.nanomedicinesummit.org

October 27-28
Michael Weiner
Present
Nanostart�s Stock Day 2004 Nanotech
Japan Center in Frankfurt, Germany
www.stockday.de

October 27 John Lanzafame Present NANOMATERIALS 2004: Emphasizing Biotechnology and Biomedicine
Stamford Marriott, Stamford, CT
www.bccresearch.com/nanobio2004
October 28 John Lanzafame Present BEACON Annual Symposium and Technology Fair
" BioNanotechnology: The World of the Small in Medicine"
Heublein Education and Resource Center, Hartford, CT
www.bionanotechnology2004.org.
November 11-12
Sarah Cooper
Present
Nano2004 Conference
Wyndham Inner Harbor Hotel, Baltimore, MD
www.techbriefs.com/nano
November 15-16 Michael Weiner Present/Exhibit Nanotechnology: Innovation, Opportunity, & Commercialization
Rensselaer Polytechnic Institute, Troy, NY
www.alumni.rpi.edu/nanotech.html.
November 18
Michael Weiner Attend/Exhibit
Medical Applications for Nanotechnology
Location TBD - San Diego, CA
More information to follow
November 28 - December 3
Michael Weiner
Stu MacDonald
Jeff Helfer Attend/Exhibit
The Radiological Society of North America 90th Scientific Assembly and Annual Meeting
McCormick Place, Chicago
www.rsna.org

[trickygirl]

Biophan Technologies präsentiert auf der WallSt.net Small Cap Konferenz
Donnerstag 21. Oktober 2004, 16:07 Uhr



ROCHESTER, N.Y.--(BUSINESS WIRE)--20 Okt 2004--Biophan Technologies, Inc. (OTC BB: BIPH), ein Entwickler biomedizinischer Technologie der nächsten Generation, hat angekündigt, dass die Gesellschaft den Investmentprofis, die am Freitag, dem 22. Oktober, an der WallSt.net Small Cap Konferenz in Beverly Hills, Kalifornien, teilnehmen werden, einen Firmenüberblick geben wird. Sprecher wird Vorstandsvorsitzender Michael Weiner sein.
Die WallSt.net Small Cap Konferenz findet im Hotel Four Seasons in Beverly Hills, CA, statt. Die Teilnehmer sind Small-Cap-Broker, Fond-Manager und Investmentbanker.

Weiner wird die führende Rolle von Biophan bei der Entwicklung von Technologien diskutieren, mit denen implantierbare, biomedizinische Vorrichtungen und chirurgische Instrumente sicher und problemlos mit der Kernspintomografie (MRI) betrieben werden können. Er wird außerdem neue Technologieinitiativen der Gesellschaft vorstellen.

"Ich freue mich auf das Treffen mit den Investmentprofis aus dem Raum Los Angeles, die an dieser Konferenz teilnehmen werden, sagte Weiner. "Biophan hat kürzlich mehrere wichtige neue Initiativen im Bereich der Biomedizintechnik vorgestellt, darunter die MRI-Kontrastmittel NanoView, implantierbare und durch Körperwärme angetriebene Batterien und Arzneimittelabgabetechniken. Darüber hinaus verfügen wir über Technologien, um Geräte kernspinsicher und kernspintauglich zu machen. Vor kurzem haben wir unsere Effektivität, darunter unsere "Anti-Antennen"-Technologie demonstriert. Vier unserer sechs Technologien nutzen Fortschritte im Bereich der Nanotechnologie und wir haben mittlerweile 92 Patente erteilt bekommen oder angemeldet. Wir werden außerdem unsere Partnerentwicklungsprogramme mit der NASA und Boston Scientific (NYSE: BSX) vorstellen."

[trickygirl]

MW will be presenting to this Small-Cap Discovery Conference on Dec. 9, 2004.

Thursday, December 09th, 2004
7:30 am -- 5:00 pm EST

Le Parker Meridien
118 West 57th Street
New York, NY 10019 United States




Wall Street Reporter`s Small-Cap Discovery Conference will showcase the most dynamic small- and micro-cap companies in the for an audience of more than 120 influential analysts, fund managers and institutional investors.


This forum provides a unique venue to reach influential members of the financial community, as well as an opportunity for investors and analysts to gain an in-depth look at innovative companies across numerous industries including: technology, healthcare, consumer, and financial services.


Who¹ll be there?


o Fund Managers o Industry Analysts

o Venture Capitalists o Investment Bankers

o Industry Executives o Media


For CEO¹s: Meet face-to-face with analysts and investment professionals from leading firms, such as: Goldman Sachs, JP Morgan Chase, CSFB, Deutsche Bank, Merril Lynch, Morgan Stanley, UBS Warburg and many more.

[vanillaicebaer]

December 4
Michael Weiner Present
Presentation to Private Alumni Reunion of Investors and Fund
Managers at Berlin Stock Exchange
Berlin, Germany

und noch ein weiterer Termin

December 9
Michael Weiner Present
Wall Street Reporter Small-Cap Discovery Conference
Le Parker Meridian, New York, NY
www.wallstreetreporter.com/roundtables/discoveryconference/s…

[trickygirl]

http://www.techbriefs.com/nano/speakers.html

[trickygirl]

December 4
Michael Weiner Present
Presentation to Private Alumni Reunion of Investors and Fund
Managers at Berlin Stock Exchange
Berlin, Germany


December 9
Michael Weiner Present
Wall Street Reporter Small-Cap Discovery Conference
Le Parker Meridian, New York, NY
www.wallstreetreporter.com/roundtables/discoveryconference/smallcap_conference3.html

[fritzchenI]

Diese Aktie ist ständig nur am fallen ,die gibts bald wohl unter 50 cents davon bin ich überzeugt- Hätte ich bloss damals meine Lambda noch behalten

[MicroV]

Press Release Source: Biophan Technologies, Inc.

Biophan Scientist Selected to Present Company Research to Annual Meeting of the Radiological Society of North America
Wednesday November 24, 3:29 pm ET
Senior Scientist Robert W. Gray to Report on Biophan Innovations in Design of Surgically Implanted Devices to Increase MRI Safety

ROCHESTER, N.Y.--(BUSINESS WIRE)--Nov. 24, 2004-- Biophan Technologies, Inc. (OTC BB:BIPH - News), a developer of next-generation biomedical technology, has announced that Biophan will present recent research results at the Radiological Society of North America`s (RSNA) annual scientific assembly and meeting. The announcement was made by Michael Weiner, Biophan CEO.

ADVERTISEMENT
The Radiological Society of North America is one of the world`s leading associations of radiologists and related science and health care professionals. Biophan Senior Scientist Robert W. Gray will make the presentation at RSNA`s 90th Scientific Assembly and Annual Meeting, in Chicago, IL, to be held Nov. 28 - Dec. 3.

Dr. Frank G. Shellock, a member of Biophan`s Scientific Advisory Board and a widely recognized authority on MRI safety, co-authored the presentation entitled "Design Changes to Implanted Device Leads Substantially Reduce MRI Related Heating." W.T. Bibens, a research manager at Biophan (formerly with Johnson & Johnson and Allied Signal), is also a co-author.

In his presentation, Mr. Gray will describe Biophan`s research into design modifications to leads or wires for implanted medical devices undergoing magnetic resonance imaging (MRI). Biophan`s research has demonstrated important safety implications for MRI-related heating of device leads, and can contribute to the substantial reduction in the risks associated with MRI imaging for patients with implanted devices.

"The presentation of Biophan`s findings on MRI Safety at the RSNA Scientific Assembly is an important milestone for us, and we are pleased to be selected," stated Mr. Weiner. "Dr. Shellock`s collaboration as co-author of this presentation makes the occasion much more special for us. Dr. Shellock is well-known throughout the world as one of the leading experts on MRI Safety."

Mr. Gray has been a research scientist at Biophan since 2000. He is co-inventor of several patents relating to MRI technology and safety, and holds master`s degrees in theoretical and experimental physics from SUNY Binghamton and the University of Rochester. He spent 10 years at IBM, and has published scientific papers in peer-reviewed physics and cartography journals.

Dr. Shellock, a world-renown authority on MRI safety, is Adjunct Clinical Professor of Radiology and Medicine at the Keck School of Medicine, University of Southern California and the Founder of the Institute for Magnetic Resonance Safety, Education, and Research (www.IMRSER.org). Dr. Shellock created the internationally popular web site, www.MRIsafety.com, and is author of five medical textbooks, over 60 book chapters, and more than 190 peer-reviewed articles.

About Radiological Society of North America

The mission of the Radiological Society of North America is to promote and develop the highest standards of radiology and related sciences through education and research. The Society seeks to provide radiologists and allied health scientists with educational programs and materials of the highest quality, and to constantly improve the content and value of these educational activities. The Society seeks to promote research in all aspects of radiology and related sciences, including basic clinical research in the promotion of quality healthcare. The Society seeks to foster closer fellowship among all radiologists and greater cooperation among radiologists and members of other branches of medicine and allied healthcare professionals.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have a total of 101 U.S. patents issued, pending, or allowed. This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA`s Ames Center for Nanotechnology. Biophan`s goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit http://www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan`s MRI technologies; the approval of Biophan`s patent applications; the successful implementation of Biophan`s research and development programs; the acceptance by the market of Biophan`s products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan`s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan`s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:

Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Michael Weiner, 585-214-2441


Source: Biophan Technologies, Inc.

[Cookiy]

@Fritzchen Beitrag7

Sag das nicht so laut, man hält uns sonst für ungebildet.

Ich verliere auch so langsam das Vertrauen.

[trickygirl]

Biophan Technologies, Giant Motorsports and WorldWater & Power to Present in Trilogy Capital`s Emerging Growth Microcap Forum Webcast on Nov. 30, 12:00 noon Eastern

FRIDAY , NOVEMBER 26, 2004 06:00 AM



LOS ANGELES, Nov 26, 2004 (BUSINESS WIRE) --Emerging growth microcap companies Biophan Technologies Inc. (OTCBB:BIPH), Giant Motorsports Inc. (OTCBB:GMOS) and WorldWater & Power Corp. (OTCBB:WWAT) will present strategic plans and other information about their companies in an online webcast open to all interested investors, scheduled to start at 12 noon ET on Tues., November 30.

This live over-the-Internet video presentation employs a fast-moving, highly informative format. It features on-camera presentations by CEOs with side-by-side streaming video and informational slides. The conference will be moderated by A.J. Cervantes, President of Trilogy Capital Partners.

"Trilogy is committed to identifying early-stage public companies with high growth potential," said Mr. Cervantes. "Our Microcap Forums are a powerful means of quickly conveying essential business and strategic information about these companies to assist interested investors in their research."

The Forum will last approximately 20 minutes. There is no need to pre-register. To view the webcast, simply go to www.trilogy-capital.com five or ten minutes prior to the start time and log on. The conference is free of charge and open to all interested investors.

For those unable to view the initial Nov. 30 webcast, the Forum will be archived for replay at http://www.trilogy-capital.com.

[trickygirl]

test

[BillTylor]

lustig !! Tricky

hätte schon mit den big news gerechnet !!!!

[Cookiy]

Test

[DausendUndMehr]

BIG NEWS

[AlexxS]

ja wo sind sie denn, put put put, ja wo sind sie denn?

oh die sind so verschüchtert, die trauen sich garnet raus

[trickygirl]

Biophan CEO to Speak at Bay Area Biotechnology and Healthcare Investor Forum

MONDAY , DECEMBER 06, 2004 06:00 AM



ROCHESTER, N.Y., Dec 6, 2004 (BUSINESS WIRE) --Biophan Technologies, Inc (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that its CEO Michael Weiner will present at the Bay Area Biotechnology and Healthcare Forum in Foster City, California on December 7, 2004.

Mr. Weiner will deliver his comments to an audience of biotechnology investors and other members of the biotechnology industry community. Other presenters at the Forum include Wall Street industry analysts and top executives of key biotechnology companies. The conference, organized by Informed Investors Forums, is sponsored by The Wall Street Journal, Barron`s and others.

Mr. Weiner will outline some of Biophan`s recent proprietary research and development initiatives using nanotechnologies and other patented anti-antenna procedures to enhance the safety and compatibility of implanted medical devices in the Magnetic Resonance Imaging (MRI) environment. He will also describe market opportunities for Biophan`s proprietary technologies and solutions in several multi-billion-dollar areas of the health care sector.

"I`m looking forward to illustrating for this audience the latest achievements from Biophan in the development of our important nanotechnology-based biomedical solutions," Mr. Weiner said. "Biophan is standing at the forefront of the next generation of biomedical science. This forum is an excellent opportunity to highlight for investors the impact that our science has for practitioners and patients, and to demonstrate how our technological innovations and proprietary solutions advance the safety and efficacy of MRI across a wide spectrum of diagnostic and surgical procedures."

About Informed Investors Forums

Founded in 1993, Informed Investors offers a conduit for companies to present their IR message through industry specific forums directly filters. It gives companies the opportunity to provide the transparency investors are seeking. The forums are conducted both over the Internet and in-person through onsite investor conferences. For more information, visit http://www.informedinvestors.com/index.asp and, under "On-site Forums," select "December 7, 2004 Bay Area Biotechnology and Healthcare Forum - Foster City, CA."

[MC.Schnitzel]

March 2
Michael Weiner Present
The Wall Street Analyst Forum - 16th Annual Analyst Conference
The Roosevelt Hotel
New York City, NY
http://www.analyst-conference.com/
March 16-17
Michael Weiner Present
Sachs-Bloomberg 4th Annual North America Forum for Investing & Partnering in Biotech & Medtech
Fairmont Copley Plaza
Boston, MA
http://www.sachsforum.com/boston05_fs.html
March 21-23
John Lanzafame Present
Convergence: The Drug / Device Summit
The Westin Convention Center
Pittsburgh, PA
http://www.windhover.com/dotcom/conferences/index.asp?page=c…

[2502]

[AlfredBiophan]

BW Global (GERMAN) - CEO von Biophan präsentiert auf der Konferenz " Sachs-Bloomberg North America Forum for Investing & Partnering in Biotech & Medtech"





CEO von Biophan präsentiert auf der Konferenz " Sachs-Bloomberg North America Forum for Investing & Partnering in Biotech & Medtech"

( BW)(NY-BIOPHAN-TECHNOLOGIES)(BIPH) CEO von Biophan präsentiert auf der Konferenz " Sachs-Bloomberg North America Forum for Investing & Partnering in Biotech & Medtech"

Redaktion Wirtschaft/Gesundheit/Medizin

Sachs-Bloomberg North America Forum for Investing & Partnering in

Biotech & Medtech ROCHESTER, N.Y.--(BUSINESS WIRE)-16. März 2005--

CEO Michael Weiner erläutert die Investitionsstrategien für den Biomedizintechnikmarkt, Übertragung der Präsentation per Webcast

Biophan Technologies, Inc. (OTCBB: BIPH), ein Innovationsunternehmen, das biomedizinische Technologie der nächsten Generation entwickelt, hat angekündigt, dass sich das Unternehmen auf der führenden Konferenz über Fortschritte und Investitionen in der Biotechbranche, dem Sachs-Bloomberg North America Forum for Investing & Partnering in Biotech & Medtech, präsentieren wird. Die Konferenz findet am 16. und 17. März im Plaza Hotel in Boston, MA, USA, statt.

Der Vortrag des Vorstandsvorsitzenden von Biophan, Michael Weiner, ist für heute 10.55 angesetzt. Der Audioteil der Präsentation wird simultan per Webcast übertragen. Interessierte melden sich vor dem geplanten Beginn der Rede unter http://www.vcall.com/CEPage.asp?ID=91005 an.

Weiner erläutert die fortgeschrittenen Lösungen des Unternehmens aus dem Bereiche der Nanotechnologie und anderen Bereichen sowie Produktverbesserungen für bedeutende Medizintechniksektoren, einschließlich Kernspintomographie (MRI). Er wird einige der neuesten Forschungs- und Geschäftsentwicklungen beschreiben, darunter hochmoderne Lösungen zur Steigerung der Sicherheit und Kompatibilität implantierter, medizinischer Vorrichtungen und chirurgischer Instrumente unter Kernspinbedingungen. Weiner wird außerdem eine Vorschau auf Investmentbedingungen auf wichtigen, neuen Biotechmärkten geben.

Das Forum wird gemeinsam von Sachs Associates und Bloomberg Associates organisiert. Zu den Themen der derzeit stattfindenden, zweitätigen Veranstaltung gehören: Venture-Finanzierung und Biotech-Investitionen, Bio-Partnering und Gemeinschaftsprojekte mit der Bio/LifeScience-Branche sowie Analyse der MedTech-Branche. Mehr Informationen über das Forum gibt es unter www.sachsforum.com/boston05_fs.html.

Über Sachs Associates

Sachs Associates ist eine in London ansässige Firma, die in Zusammenarbeit mit Bloomberg L.P. Konferenzen für den Anlegermarkt organisiert und veranstaltet. Die Schwerpunkte der Investmentkonferenzen von Sachs Associates liegen auf den Neuen Märkten, europäische Kapitalanlagen und Technologie und finden in den wichtigsten Finanzzentren der Welt statt, darunter in London, New York und Zürich.

Über Bloomberg L.P.

Bloomberg L.P. ist ein internationaler Multimedia-Anbieter von Informationsdiensten und liefert Nachrichten, Daten und Analysen für die Finanzmärkte und Finanzbranche. Bloomberg hat seinen Hauptsitz in New York City und produziert Echtzeit-Kurse, Daten, Kursverläufe, Analysen und elektronischen Datenaustausch 24 Stunden täglich und 365 Tage im Jahr. Bloomberg L. P. wird von mehr als 250.000 Finanzexperten in 90 Ländern weltweit genutzt.

Über Biophan Technologies

Biophan Technologies entwickelt und vermarktet neueste Technologien, mit deren Hilfe sich biomedizinische Geräte sicher und problemlos mit Kernspintomographieausrüstungen betreiben lassen. Das Unternehmen entwickelt Einsatztechnologien für medizinische Implantatsysteme, wie beispielsweise Schrittmacher, und für interventionelle chirurgische Vorrichtungen, wie Katheter und Führungsdrähte, sowie für Stents und andere Implantate, die sich sicher und wirksam durch Kernspintechnologie darstellen lassen. Die Technologie wird außerdem zur Verbesserung von Kernspin-Kontrastmitteln verwendet und wurde auf andere Anwendungen erweitert, wie beispielsweise die Arzneistoff-Delivery und durch Körperwärme angetriebene Energiesysteme. Fortschritte in der Nanotechnologie und Thin-Film-Beschichtungen sind Bestandteil von vier Produktlinien von Biophan. Biophan konzentriert sich auf Wachstum durch Innovation und einen entwicklungsorientierten Führungsstil. Das Unternehmen und seine Lizenzgeber verfügen nun über insgesamt 108 US-Patente, Lizenzen oder Anmeldungen. Davon sind 32 erteilte US-Patente, 8 kürzlich angenommene Patente, die in Kürze erteilt werden, und 68 beantragte Patente, die sich in verschiedenen Prüfstadien beim US-Patent- und Markenamt befinden, sowie internationale Patentanmeldungen. Die Patente betreffen Gebiete wie die Nanotechnologie (Nanopartikelbeschichtungen), Hochfrequenzfilter, Polymercomposite, thermoelektrische Materialien für Batterien, die Strom aus Körperwärme erzeugen, und Photonik. Biophan hat Entwicklungspartnerschaften mit Boston Scientific (NYSE:BSX) und dem Ames Center for Nanotechnology der NASA abgeschlossen. Biophan arbeitet darauf hin, alle biomedizinischen Geräte sicher und problemlos mit der Kernspintechnologie zu kombinieren. Mehr Informationen über Biophan gibt es im Internet unter www.biophan.com.

Vorsichtshinweis in Bezug auf zukunftsweisende Aussagen

Bei bestimmten, in dieser Pressemeldung enthaltenen Aussagen handelt es sich um zukunftsweisende Aussagen. Die tatsächlichen Ergebnisse können wesentlich von solchen hierin genannten oder stillschweigenden Aussagen abweichen und zwar als Ergebnis unterschiedlicher Faktoren, darunter, jedoch nicht ausschließlich: der Entwicklung der MRI-Technologien von Biophan; der Annahme der Patentanmeldungen von Biophan; der erfolgreichen Implementierung der Forschungs- und Entwicklungsprogramme von Biophan; der Akzeptanz der Produkte von Biophan auf dem Markt; von Wettbewerb und zeitlicher Abstimmung von Projekten und Trends bei der zukünftigen Geschäftsperformance, sowie anderen Faktoren, die in den Unterlagen aufgeführt sind, die Biophan regelmäßig bei der US-amerikanischen Börsenaufsichtsbehörde (der " SEC" ) einreicht. Diese Pressemeldung sollte demzufolge unter Beachtung dieser Unterlagen gelesen werden. Die hierin enthaltenen, zukunftsweisenden Aussagen gelten nur für das Datum dieser Pressemeldung und Biophan übernimmt keine Verpflichtung zur öffentlichen Aktualisierung solcher zukunftsweisenden Aussagen als aufgrund späterer Ereignisse oder Umstände.

--30--TM/ny"

KONTAKT: Biophan Technologies, Inc.

Carolyn Hotchkiss, [phone]

oder

Presse-Interviews:

Jennifer Gould, [phone] ESHEET: 4844210

[Bachalor]

termin ist

ab ostermontag um 16.30 börseneröffnung

[CyberCoach]

Biophan CEO Michael Weiner Discusses New Milestones in Intellectual Property Portfolio with SmallcapInsights.com
Latest Biomedical Patents and Patent Applications Discussed As Portfolio Grows to 114 Patents Issued and Pending

LOS ANGELES, March 29, 2005 (PRIMEZONE) -- SmallcapInsights.com, www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an audio interview with Michael Weiner, CEO of Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology.

In the audio interview with SmallcapInsights.com, Mr. Weiner explained the importance of the recent issued patents and patent applications. Biophan`s growing intellectual property portfolio now consists of 114 patents, licenses or applications, in technology areas such as nanotechnology, photonics and others. That total now includes a new total of 34 patents issued, with eight recently allowed applications and 72 pending applications at various stages of examination. Biophan is leveraging its extensive intellectual property to capitalize on opportunities in several multi-billion-dollar biomedical markets, including drug-delivery systems and the creation of implantable medical devices, such as stents and catheters, that are safe and image-compatible with Magnetic Resonance Imaging (MRI) systems.

The streaming audio interview can be accessed at http://www.SmallcapInsights.com. Registration to listen to the interview is free.

About Smallcap Insights

Smallcap Insights provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. Smallcap Insights strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at www.SmallcapInsights.com

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 34 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA`s Ames Center for Nanotechnology. Biophan`s goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan`s actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan`s ability to develop its technologies; the approval of Biophan`s patent applications; the successful implementation of Biophan`s research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan`s technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan`s technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan`s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan`s periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Compensation and Other Disclosures

Smallcap Insights is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by Smallcap Insights are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Biophan of $12,500 per month through February 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. A subsidiary of Trilogy has entered into an agreement with a non-affiliate shareholder of this company pursuant to which the subsidiary has agreed to purchase from time to time from the third party under certain conditions up to an aggregate of 6,380,000 shares of common stock of this company at prices ranging from $.60 to $2.00 per share.

CONTACT: Smallcap Insights
Astra Gomez
800-592-6061

[CyberCoach]

Biophan to Participate in Expert Panel on Intellectual Property at Pennsylvania Nanotechnology Conference

MONDAY , APRIL 18, 2005 03:30 AM

ROCHESTER, N.Y., Apr 18, 2005 (BUSINESS WIRE) --Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced that John Lanzafame, President of the Nanolution drug delivery division of Biophan, is scheduled to participate on an expert panel at the Pennsylvania Nanotechnology Conference, to be held at the Westin Convention Center Hotel in Pittsburgh, PA, April 18-20.

Mr. Lanzafame is scheduled to take part in a panel entitled, " Emerging Nanotech Strategies: Getting the Biggest Bang for Your Buck," at 11 a.m., on April 20th. The panel is designed to present a range of perspectives from industry experts on strategies that can be employed to generate greater return on nanotech intellectual property investments. Mr. Lanzafame will discuss Biophan`s strategies in the expansion of its intellectual property portfolio, including the Company`s successful ongoing initiatives to create " patent thickets" to protect proprietary technologies and potential markets. Other topics expected to be covered include the importance of early planning in the patent process to ensure optimal value from intellectual property portfolios.

" Biophan is an intellectual property-driven company, and we have developed extensive experience in intellectual property development and strategies," said Mr. Lanzafame. " Since its inception, Biophan has pursued a very aggressive program to build up a commanding patent and intellectual property portfolio, at last count totaling 114 U.S. issued patents, licenses, or applications. It`s an important part of our plan to deliver next-generation technology and cutting-edge products to the marketplace, while protecting these technologies and ensuring the greatest value for the Company and its shareholders."

[trickygirl]

Von vanilla aus dem Hauptthread:

May 5-7 Heart Rhythm 2005 (Exhibit)
Company Representative(s):
Michael Weiner
Stu MacDonald
Michael Riedlinger
John Lanzafame
Tim Bibens

May 6-8 International Society for Magnetic Resonance in Medicine (ISMRM)
www.ismrm.org
Company Representative(s):
Michael Friebe, Ph.D., President, Biophan Europe

May 10-12 17th Annual Las Vegas Money Show (Present/Exhibit)
Las Vegas, NV
Company Representative(s):
Michael Weiner (Presenting)
Carolyn Hotchkiss (Exhibiting)
Ginny Quinn (Exhibiting)

May 9-12 NSTI Nanotech Ventures 2005 (Present)
http://www.nsti.org/NanotechVentures2005/
Company Representative (s):
Michael Weiner

May 11 NSTI Public Equity Markets and Alternatives for Nanotechnology
Company Representative (s):
Michael Weiner

[Bachalor]

ne menge neuer termine
http://www.biophan.com/conferences.php

May 22-25
4th Annual NanoBusiness Conference 2005 (Present)
http://www.nanoevent.com/
New York Marriott Financial Center
85 West Street
New York City, NY

Company Representative (s):
Michael Weiner

June 6-8
Pacific Growth Equities Life Science Growth Conference (Attend)
http://www.pacificgrowth.com/conference/index.html
Mark Hopkins InterContinental Hotel
Number One Nob Hill
San Francisco, CA 94108

Company Representative (s):
Michael Weiner

June 13-14
NanoEquity Europe 2005 Conference (Present)

Hotel Hilton Frankfurt
Hochstrasse 4
Frankfurt, Germany

Company Representative(s):
Michael Weiner

June 13-15
Medical Design & Manufacturing East 2005 (Exhibit)
Medical Design & Manufacturing East 2005
Jacob K. Javitz Convention Center
655 W. 34th Street (at 11th Avenue)
New York, NY

Company Representative(s):
John Lanzafame

June 23-24
Pharma Finance 2005 (Present)
http://www.milanogroup.com/pharmafinance2005
Jolly Hotel
Villa Carpegna
Via Pio IV, 6
Rome, Italy

Company Representative(s):
Michael Weiner

August 25-27
Frontiers of Science Within Nanotechnology (Present)
http://physics.bu.edu/icamnano/
Boston University

Company Representative(s):
Michael Weiner

September 14-15
ValueRich International Public Company Assembly and Exposition
(Present)
http://valuerichonline.com/convention/index.php
Jacob K. Javitz Center
New York City, NY

Company Representative(s):
Michael Weiner

October 4-5
Sachs Bloomberg 5th Annual Biotech in Europe Forum (Present)
http://www.sachsforum.com/zurich.html
Swissotel
Zurich, Switzerland

Company Representative(s):
Michael Weiner

October 16-20
Licensing Executives Society (LES) (USA-Canada) 2005 Annual
Meeting (Present)
http://www.usa-canada.les.org/meetings/2005annual/
Meeting location to be announced
Phoenix, AZ

Company Representative(s):
Michael Weiner

October 19
11th Bioscience Economy Conference (Present)
http://www.capitalife.com/bioscience_conference.html
Meeting location to be announced
Geneva, Switzerland

Company Representative(s):
Michael Weiner

October 20
11th Bioscience Economy Conference (Present)
http://www.capitalife.com/bioscience_conference.html
Meeting location to be announced
Milano, Italy

Company Representative(s):
Michael Weiner

November 5-6
MRI Safety Workshop: Update, Practical Information and Future
Implications and ISMRM Sponsored Workshop (Sponsor)
http://www.ismrm.org/workshops/index.html
Hilton McLean Tyson`s Corner
McLean, VA

Company Representative(s):
Michael Weiner